Stigmasterol for the treatment of alzheimer's disease

A technology for Alzheimer's disease and stigmasterol, which is applied in the field of treatment of Alzheimer's disease and β-amyloid peptide amyloidosis, and can solve the problems of not providing special preparations

Inactive Publication Date: 2012-04-18
NUTRICIA
View PDF12 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] In general, the prior art provides little or no teaching that would assist the skilled artisan in formulating specific form

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stigmasterol for the treatment of alzheimer's disease
  • Stigmasterol for the treatment of alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1: In vitro assay of γ-secretase activity

[0069] Material

[0070] Campesterol, ergosterol, β-sitosterol, stigmasterol and cholesterol were obtained from SIGMA ALDRICH. For in vitro assays, 10 mM stock solutions in ethanol were prepared and stored at -20°C under non-oxidizing conditions.

[0071] cell culture

[0072] Human neuroblastoma cell line SH-SY5Y-wt was cultured in Dulbecco's Modified Eagle's Medium (DEMEMALDRICH) supplemented with 10% fetal calf serum (FCS) and 1x non-essential amino acid solution (MEM, SIGMAALDRICH) ..

[0073] 100% confluent (confluent) cells were cultured in DMEM containing 0.1% FCS+MEM for 48h (2 x 24h) before harvesting.

[0074] In vitro assay of γ-secretase activity

[0075] To prepare total membranes, SH-SY5Y-wt. (treated as above), scrape and rupture in a buffer containing 10 mM Tris-HCl pH 7.4. After isolation of the total membrane by ultracentrifugation, the resuspended membrane was incubated with 100 [mu]M st...

Embodiment 2

[0083] Example 2: In vitro assay of γ-secretase activity

[0084] Introduction

[0085] One of the hallmarks of Alzheimer's disease (AD) is the formation of β-amyloid plaques. β-amyloid is formed from amyloid precursor protein (APP) through the sequential action of two secretases, β-secretase and γ-secretase. The APP protein is a protein normally produced in humans and animals and exerts normal physiological functions. In AD, however, the actions of β- and γ-secretases are enhanced, leading to toxic β-amyloid accumulation. Therefore, preventing or slowing down the action of γ-secretase will reduce β-amyloid formation. This experiment tested whether stigmasterol could affect the activity of γ-secretase in mouse brain tissue.

[0086] method

[0087] For this purpose, 2 groups of mice were fed a diet containing stigmasterol (ST) or a diet without stigmasterol (control). These chows were provided to the mice for 4 weeks, after which brain tissue was collected. Brains...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of stigmasterol in the manufacture of a nutritional or pharmaceutical composition for prophylactic or therapeutic treatment of amyloidosis of beta-amyloid peptide (Ab) in a mammal. Further, the invention relates to the use of stigmasterol in the manufacture of a nutritional or pharmaceutical composition for prophylactic or therapeutic treatment of Alzheimers disease.

Description

technical field [0001] The present invention relates to the use of stigmasterol for treating amyloidosis, especially amyloidosis of β-amyloid peptide (Aβ), and for treating Alzheimer's disease. Background technique [0002] In the medical field, amyloidosis refers to a variety of conditions in which amyloid is abnormally deposited in organs and / or tissues. Proteins or peptides are described as amyloid if, due to changes in their secondary structure, they assume a specific aggregated insoluble form similar to β-sheets. Symptoms vary widely depending on the site of amyloid or peptide (amyloid) deposition. [0003] Cerebral amyloidosis is a prominent aspect of Alzheimer's disease for which there is currently no cure and which affects a significant proportion of the population, especially the elderly. Several publications report in general terms that patients suffering from various age-related diseases can benefit from specific classes of compounds, for example, from plants. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L1/30A61K31/575
CPCA23L1/3004A23V2002/00A61K31/575A23L33/11A23V2200/322A23V2250/21376
Inventor 马库斯·奥托·沃尔特·格林托别斯·哈特曼彼得拉·弗里斯-雅福尔科瓦乌尔里希·劳弗斯奥利弗·魏因格特纳
Owner NUTRICIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap